Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEGFR-2 siRNA
- Development stage
- Preclinical
- Lead developer
- Osaka City University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
VEGFR-2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2), a key mediator of angiogenesis and tumor progression. By utilizing the RNA interference (RNAi) pathway, the siRNA sequence specifically targets and promotes the degradation of VEGFR-2 mRNA, thereby reducing the protein expression of the receptor on the cell surface. In preclinical research, particularly in pancreatic cancer models, VEGFR-2 siRNA has been shown to significantly inhibit the migration and invasion of cancer cells by disrupting the VEGF-A/VEGFR-2 signaling axis and its downstream effectors, such as MAPK and PI3K. This modality is primarily explored as a targeted approach to overcome the limitations of systemic inhibitors and to validate VEGFR-2 as a therapeutic target in solid tumors.
- Other names
- VEGF-R2 siRNAVEGF-R-2 siRNAVEGF-R 2 siRNA
02
Targets
Vascular endothelial growth factor receptor 2 (VEGFR2) messenger RNA
Beyond the preview
Go deeper on VEGFR-2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VEGFR-2 siRNA.